Can Liraglutide Protect Nerves from Chemotherapy Damage?

Weekly liraglutide injections reduced nerve pain, improved motor function, and decreased inflammation in rats with cisplatin-induced peripheral neuropathy.

Ozatik, Fikriye Yasemin et al.·Journal of molecular histology·2025·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-12902Animal StudyPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
N=32
Participants
N=32 female Sprague Dawley rats in 4 groups. Neuropathy induced by cisplatin 3 mg/kg/week for 5 weeks.

What This Study Found

Liraglutide, especially at weekly dosing, reduced cisplatin-induced neuropathic pain, motor impairment, and nerve tissue damage in rats.

Key Numbers

  • 32 rats in 4 groups of 8
  • Cisplatin dose: 3 mg/kg/week for 5 weeks
  • Liraglutide given once weekly or daily
  • Weekly liraglutide was more effective than daily
  • Markers measured: SOD, CAT, GPx (oxidative stress); NO, IL-6, IL-10 (inflammation)

How They Did This

Preclinical study in 32 female Sprague Dawley rats divided into 4 groups with behavioral, biochemical, and histological analysis.

Why This Research Matters

Chemotherapy-induced peripheral neuropathy affects many cancer patients and has no effective treatment. GLP-1 agonists could address this unmet need.

The Bigger Picture

GLP-1 receptor agonists continue to show neuroprotective properties beyond metabolic effects, potentially opening new therapeutic avenues for chemotherapy side effects.

What This Study Doesn't Tell Us

Animal study; results may not translate to humans. Only one chemotherapy agent tested. Small group sizes.

Questions This Raises

  • ?Would liraglutide show similar neuroprotective effects in human cancer patients?
  • ?Why was weekly dosing superior to daily?

Trust & Context

Key Stat:
Weekly > Daily Weekly liraglutide was more effective than daily dosing for protecting against chemotherapy-induced neuropathy
Evidence Grade:
Preclinical animal study. Promising but requires human clinical trials for translation.
Study Age:
Published in 2025.
Original Title:
The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.
Published In:
Journal of molecular histology, 56(3), 153 (2025)
Database ID:
RPEP-12902

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can GLP-1 drugs prevent chemotherapy nerve damage?

In this rat study, liraglutide significantly reduced chemotherapy-induced nerve damage. Human trials are needed to confirm this potential benefit.

Why was weekly dosing better than daily?

The study found weekly administration more effective but did not fully explain the mechanism. It may relate to how liraglutide modulates inflammation over time.

Read More on RethinkPeptides

Cite This Study

RPEP-12902·https://rethinkpeptides.com/research/RPEP-12902

APA

Ozatik, Fikriye Yasemin; Teksen, Yasemin; Ozatik, Orhan; Çengelli Unel, Cigdem; Karadeniz Saygili, Suna. (2025). The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.. Journal of molecular histology, 56(3), 153. https://doi.org/10.1007/s10735-025-10440-4

MLA

Ozatik, Fikriye Yasemin, et al. "The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.." Journal of molecular histology, 2025. https://doi.org/10.1007/s10735-025-10440-4

RethinkPeptides

RethinkPeptides Research Database. "The effects of the GLP1 analog liraglutide on allodynia and ..." RPEP-12902. Retrieved from https://rethinkpeptides.com/research/ozatik-2025-the-effects-of-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.